COVID-19 vaccine developed by Pfizer/BioNTech had an excellent safety profile and remarkably high efficacy (100%) in teenagers. The original study included patients ≥16 years of age and further study was needed for an even younger population that needed to go back to school.  Same as in December 2020, NEJM was the magazine chosen to publish…